Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Valiant Laboratories's average EPS without NRI Growth Rate was 9266.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Valiant Laboratories (NSE:VALIANTLAB) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Valiant Laboratories 3-Year EPS without NRI Growth Rate Related Terms
NSE:VALIANTLAB vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's 3-Year EPS without NRI Growth Rate falls into.
Valiant Laboratories 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.00% mean?
Valiant Laboratories (NSE:VALIANTLAB) has a 3-Year EPS without NRI Growth Rate of 0.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Valiant Laboratories and its competitors. According to the industry distribution chart, Valiant Laboratories ranks #999999 out of 785 companies in the Drug Manufacturers industry.
Is Valiant Laboratories' 3-Year EPS without NRI Growth Rate too high?
Valiant Laboratories' current 3-Year EPS without NRI Growth Rate is 0.00%. Based on the distribution chart, Valiant Laboratories ranks #999999 out of 785 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Valiant Laboratories has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #999999 out of 785 companies for 3-Year EPS without NRI Growth Rate. This places Valiant Laboratories in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current 3-Year EPS without NRI Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹156.46, compared to a current price of ₹91.66 — trading 41.4% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 0.00%. Valiant Laboratories' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹91.66 is trading 41.4% below its estimated GF Value™ of ₹156.46.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
3-Year EPS without NRI Growth Rate: 0.00%
GF Value™: ₹156.46 vs. price of ₹91.66 (41.4% below fair value)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
49GF Score
Get the complete analysis for NSE:VALIANTLAB
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
